GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Test GSK256073 in Patients With Dyslipidemia

Phase 2

Completed

Conditions: Dyslipidaemias
Dyslipidemias

Interventions: Drug: Placebo
Drug: Niaspan
Drug: GSK256073

First Posted Date: 2009-05-18

Last Posted Date: 2019-12-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 80

Registration Number: NCT00903617

Locations: 🇺🇸
GSK Investigational Site, Seattle, Washington, United States

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Phase 1

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Other: Placebo
Drug: eltrombopag olamine

First Posted Date: 2009-05-18

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 98

Registration Number: NCT00903422

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

28 Day Repeat Dose in Cystic Fibrosis Patients

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Drug: SB656933

First Posted Date: 2009-05-18

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 146

Registration Number: NCT00903201

Locations: 🇮🇱
GSK Investigational Site, Petach Tikva, Israel

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

Phase 3

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters)

First Posted Date: 2009-05-18

Last Posted Date: 2017-10-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 188

Registration Number: NCT00903409

Locations: 🇺🇸
GSK Investigational Site, Seattle, Washington, United States

Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults

Phase 2

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Pneumococcal vaccine GSK2189242A (formulation 1)
Biological: Pneumococcal vaccine GSK2189242A (formulation 2)

First Posted Date: 2009-05-11

Last Posted Date: 2018-08-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 43

Registration Number: NCT00896064

Locations: 🇧🇪
GSK Investigational Site, Gent, Belgium

Safety and Efficacy Study in Patients With Major Depressive Disorder

Phase 2

Completed

Conditions: Depressive Disorder

Interventions: Drug: GSK163090 Placebo
Drug: GSK163090 1 mg
Drug: GSK163090 3 mg

First Posted Date: 2009-05-11

Last Posted Date: 2018-03-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 99

Registration Number: NCT00896363

Locations: 🇷🇺
GSK Investigational Site, Tomsk, Russian Federation

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: Immunotherapeutic GSK2132231A

First Posted Date: 2009-05-11

Last Posted Date: 2021-04-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00896480

Locations: 🇫🇷
GSK Investigational Site, Villejuif, France

A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: GSK1322322/placebo
Drug: GSK1322322/placebo and midazolam

First Posted Date: 2009-05-11

Last Posted Date: 2017-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 52

Registration Number: NCT00896558

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Phase 2

Completed

Conditions: Mumps
Measles
Varicella
Rubella

Interventions: Biological: Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)
Biological: GSK Biologicals' 208136, new formulation

First Posted Date: 2009-05-05

Last Posted Date: 2019-11-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 501

Registration Number: NCT00892775

Locations: 🇨🇳
GSK Investigational Site, Taipei, Taiwan

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Phase 3

Withdrawn

Conditions: Cancer
Chemotherapy-Induced Nausea and Vomiting
Nausea and Vomiting
Solid Tumor Cancer

Interventions: Drug: Dexamethasone
Drug: IV casopitant (active)
Drug: IV casopitant (placebo)
Drug: Ondansetron

First Posted Date: 2009-05-01

Last Posted Date: 2015-04-17

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00891761

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy